non-small-cell lung cancer
Conditions
Interventions
experimental group:Albumin-bound paclitaxel maintenance therapy
Sponsors
Yunnan Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Aged >=18 years; 2) Patients with stage IIIB, IIIC and IV lung squamous cell carcinoma diagnosed by histology or cytology; 3) At least one objective lesion (CT, MRI or X-ray, etc.) can be measured or evaluated by imaging examination; 4) Did not receive chemotherapy; 5) Expected survival time >=3 months; 6)ECOG physical condition score 0~1; 7) Peripheral blood was basically normal: Absolute count of neutrophils (ANC) : >=1.5x10^9/L; Platelet count (PLT): >=100x10^9/L; Hemoglobin (Hb) level >=90g/L; 8) No obvious abnormalities in cardiac, hepatic and renal function: Total bilirubin (TBil) level: <=1.5 ULN; The levels of AST and ALT were <=2.5 ULN, and <=5 ULN in the presence of liver metastasis.Serum creatinine <=1.5 ULN; Electrocardiogram was basically normal without contraindications of chemotherapy; 9) Subjects have good compliance, can conduct treatment and follow-up, and voluntarily comply with the provisions of this study; 10) Subjects of childbearing age must agree to use effective contraception during the study period;Serum or urine pregnancy tests must be negative in women of childbearing age 72 hours before chemotherapy begins;The female must be non-lactating; 11) Sign the informed consent; 12) Patients with advanced lung squamous cell carcinoma who have been denied genetic testing or who have been genetically negative. Maintain chemotherapy inclusion criteria: 1) Remission (CR+PR) was achieved 12 weeks after first-line chemotherapy without progression; 2)Physical condition can tolerate subsequent treatment, ECOG physical condition score 0~1;
Exclusion criteria
Exclusion criteria: 1) There is brain metastasis; 2) Uncontrolled severe medical conditions that the investigator believes will affect the subject's treatment with the study protocol;Dementia, change of mental state or any mental illness that would prevent understanding or informed consent or the completion of a questionnaire; 3) A history of allergy or hypersensitivity to any therapeutic ingredient; 4) Malignant tumors other than NSCLC within 5 years, except basal cell or squamous cell skin cancer that is adequately treated, local prostate cancer after radical surgery, and ductal carcinoma in situ after radical surgery; 5) Subjects with >=2 grade peripheral neuropathy according to CTCAE V 4.03; 6) HBsAg positive subjects with peripheral blood HBV DNA titer >=1x10^3 IU/mL; 7) Hepatitis C virus (HCV) antibody positive or human immunodeficiency virus (HIV) antibody positive; 8) Need to be combined with other anti-tumor drugs; 9) Has been treated with any other experimental drug or participated in another interventional clinical trial within 30 days of the screening period; 10) The researcher thinks it is not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival; | — |
Countries
China
Contacts
Public ContactLi Gaofeng
Yunnan Cancer Hospital
Outcome results
None listed